Abstract
Autoimmune diseases are a spectrum of clinical conditions characterized by systemic manifestation with circulating antibodies against the patient's own tissues with the exception of CD in which no identifiable autoantibody is known 1 . Genetic susceptibility is an essential pre-requisite condition for the pathogenesis of autoimmune diseases, although the molecular mechanisms of most autoimmune diseases are unclear 1 . Recent advances of microbiome research demonstrated that the surface area of human body including body cavities is covered by a plethora of microbes (commensal), and these microbes are essential in host defense against pathogens, innate and adaptive immunity development and prevention of a variety of diseases 2, 3 . The symbiotic relationship of the human body with its own microbes becomes an interesting issue in the pathogenesis of infection, immunity and various degenerative diseases.
Decades ago the discovery of anti-streptolysin O antibody in the circulation of patients with streptococcal infection (pharyngitis) cross reacting with human valvular tissue and renal glomerular tissue leading to valvular heart disease and glomerulonephritis provides the basis of understanding the mechanism of streptococcal infection and the related disease process, which led to new treatment and preventive strategy 4 , 5 . In our effort to determine the role of mycobacterial infection in CD, we found there are elevated antibody levels in the patient's circulation against a panel of microbial proteins. These anti-microbial antibodies can cross-react with human tissue, potentially leading to dysfunction of human tissue and various clinical conditions. The elevated levels of antimicrobial antibodies can be used as diagnostic tools for assessment of the relationship and compatibility between the host and its own microbes, and the presence of antimicrobial antibodies provide a new direction of research in understanding the mechanism of autoimmune diseases.
Methods
1, Western blot analysis using the microbial cell extracts and the patients' plasmas as primary antibodies:
In order to determine if the human plasma from the patients with CD and SS react to the microbial proteins, the whole microbial extracts from S. aureus, S. pseudintermedius, E.
coli, MAP and MAH are prepared and Western blot analysis is performed as described 6 .
Briefly, the microbial culture (1.0 ml) in the appropriate media is centrifuged at 15,000 g for 5 minutes. The microbial cell pellet is washed with 100% acetone once, and resuspended in 1% SDS at 4 0 C overnight to extract cellular proteins. The protein concentration is determined by using Qubit protein quantification kit (Fisher Scientific).
The whole microbial extracts (20 ug) are subjected to 10% SDS-polyacrylamide gel electrophoresis and the cellular proteins are electroblotted onto nitrocellulose membrane.
The microbial proteins on the nitrocellulose membrane are incubated with the plasma (1 to 50 dilution) from patients with CD and SS at room temperature for 2 hours (or 4 0 C overnight), and secondary antibodies and detection systems are provided by using the Pierce enhanced chemiluminescent detection kit (Fisher Scientific) according to the manufacturer's instruction. (Table 1) .
3, Immunohistochemical staining of human tissue with specific anti-microbial antibodies:
Frozen section slides of human tissues were purchased commercially and used directly for immunohistochemical staining 6 . The primary antibodies against EF-Tu of Table 1 , a list of commercial antibodies are purchased (Table 1) , and tested in the modified sandwich ELISA assays 6 . Briefly, the 96-well plate (ELISA plate) is coated with the specific antibody in Table 1 or Escherichia. Coli but not both ( Figure 1B and 1C, S135, E42, E39).
We used the same patients' plasmas and the bacterial extracts to perform the immunoprecipitation and mass spectrometry to determine the identities of these bacterial/mycobacterial proteins reactive to patients' plasmas. Nanospray LC mass Spectrometry and protein identification were performed at the Poochon Scientific LLC, Frederick, MD, and a list of potential bacterial/mycobacterial candidates are provided to us after the database search, and only the proteins with same molecular weights are considered for further validation (Table 1 ). There are seven microbial proteins identified from the four microbes: S135 is determined to be DNA-directed RNA polymerase subunit B (RPOB) from S. aureus. RPOB is a critical enzyme for bacterial gene transcription. It is also a clinically relevant target for rifampin, one of the most important drugs for tuberculosis. Mutation of the RPOB gene confers rifampin resistance in E.coli, S. aureus and Mycobacterium tuberculosis. S75 represents a bacterial protein from S.
pseudintermedius, a commensal bacteria on the surface of a domestic dog with potential to be pathogenic in humans 7, 8 . The strain of S. pseudintermedius was isolated from a dog with a skin ulcer (hot spot, moist dermatitis), and the isolate was confirmed by partial 16S rDNA and whole genomic sequencing (data not shown). Using Western blot analysis and immunoprecipitation of plasmas of two separate patients with CD as the primary antibodies and using mass spectrometry, S75 was determined to be elongation factor G (EF-G) from S. aureus. EF-G is a critical regulator of bacterial protein synthesis, and it is present in all bacteria species. The human homologue is present in the mitochondria (G elongation factor mitochondrial 1, GFM1), and it plays similar roles in human protein biosynthesis. The homology between the bacterial protein and the human protein at the amino acid levels is 61% (Table 1) . M60 is a protein from MAP/MAH, and M60 is determined to be heat shock protein 65 (hsp65). The human homologue is the human hsp60, a molecular chaperone known to be an autoantigen in cancer patients and other autoimmune diseases 9, 10 . S55 is a bacterial protein seen in S. aureus and S.
pseudintermedius and it is determined to be ATP synthase alpha from S. aureus, and M. 
3, Elevated levels of anti-microbial antibodies in patients with CD and SS:
The specific polyclonal and monoclonal antibodies against the microbial proteins (Table   1 ) are used for modified sandwich ELISA assays to determine the anti-microbial antibodies in the blood of the patients with CD and SS. In total, 44 plasma samples are available from the CD patients with 31 normal healthy controls, and 26 plasma samples from SS patients (Figure 3 ). In the CD patients, 41 patients' plasma samples were positive for one or more markers (93%; all markers were positive in 14 patients, 4 markers were positive in 7 patients, 3 markers were positive in 8 patients, 2 markers were positive in 8 patients, 1 marker was positive in 4 patients, all markers were negative in 3), 14 patients were positive for all five markers (32%), and 3 patients were negative for all the five markers (7%). In contrast, there are 6 patients positive for one or more markers in 31 controls (19%) (All markers were positive in 0 patient, one or more markers were positive in 6 patients). The levels of all five markers are significantly elevated in CD patients compared to the normal controls by unpaired Student t-test (p=0.031 for hsp65 to p<0.0001 RPOB and EF-Tu) ( Figure 3A ).
Among the five serological markers, hsp65 from Mycobacterium appears less differentiating with overlapping mean data points, and it is difficult to separate the patients versus the normal controls with large overlapping results and the borderline range, although the difference of the levels in patients and the controls is significant by the unpaired Student t-test (p=0.031). All other four markers are easily separable between the CD patients and the normal controls with small overlapping ranges ( Figure   3A ). There is a cutoff value in each marker when it is measured, and each cutoff value is determined separately based on the property of each antibody used ( Figure 3A) . We did not correlate the disease severity with specific antibody titers, and we did not test if these serologic markers are useful for monitoring the treatment effect or efficacy.
In total, 26 plasmas from patients with SS are available for analysis, and 22 patients are positive for one or more markers (83%; 6 patients were positive for all markers, 4 patients were positive for 4 markers, 7 patients were positive for 3 markers, 4 patients were positive for 2 markers, 1 was positive for 1 markers), and 4 patients are negative for all markers (17%) ( Figure 3B ). All five markers showed statistically significant differences in the SS patients versus the controls by the unpaired Student t-tests ( Figure   3B ).
Interpretation
The patient population of all autoimmune diseases is increasing and the underlying causes of all these autoimmune diseases are unknown. Much of the research effort is directed to discover the autoantibodies, and the treatment strategy is directed to suppress the immune system through various mechanisms. We have found a group of antibodies against the microbial proteins and these microbes commonly cover the surface of the human body or in the case of mycobacteria, are widely present in the environment such as water and soil. S. pseudintermedius is a commensal bacterium on the surface of domestic dogs, and there are millions of families with domestic pets in the US.
There is a symbiotic relationship between the common microbes and the human hosts. In classic immunology, the pathogenic microbes are cleared by the innate immunity system (non-specific immunity). The development of specific circulating antibody against specific microbial protein is likely a result of the failed innate immunity which consists of non-specific defense system such as body barriers including surface skin and mucosa lining through body cavities, and the blood defense system including neutrophils, A B
